SHP Pharmacy Updates - effective 1/3/2012
As of January 3, 2012, the growth hormones, Nutropin®, Nutropin AQ ®, Nutropin AQ NuSpin®, Saizen®, Valtropin®, Accretropin®, and Zorbtive®, will become non-preferred medications. In addition to ensuring that the clinical indication for use meets the State Health Plan's conditions for coverage, these medications will also be subject to step therapy.
As of January 3, 2012, all prescriptions for Travatan Z® will require a coverage review. The preferred glaucoma medications latanoprost (Xalatan®) and Lumigan® will continue to be covered without a review.
Beginning January 3, 2012 (and in addition to existing coverage criteria), new users of interferon beta-1a (Rebif®) and interferon beta-1b (Extavia®) must have tried and been intolerant to or failed treatment with either interferon beta-1b (Betaseron®), interferon beta-1a (Avonex®), or glatiramer acetate (Copaxone®).